AIMS/HYPOTHESIS: IL-15, induced by innate immune stimuli, promotes rheumatoid arthritis and inflammatory bowel disease. However, its role in autoimmune type 1 diabetes is unclear. Our aim is to define the role of IL-15 in the pathogenesis of diabetes in the NOD mouse model. METHODS: We generated NOD.Il15(-/-) mice expressing a polyclonal repertoire of T cell antigen receptor (TCR) or a transgenic TCR and monitored diabetes onset and insulitis. NOD Scid.Il15(-/-) (full name NOD.CB17-Prkdc (scid)/NCrCrl) and NOD Scid.gamma (full name NOD.Cg-Prkdc(scid) Il2rg ( tm1Wjl )/SzJ) mice were used to distinguish the requirement for IL-15 signalling in CD8(+) T cells and antigen-presenting cells (APCs) to induce disease. We examined the effect of blocking IL-15 signalling on diabetes onset in NOD mice. RESULTS: At 7 months of age, more than 75% of the NOD Il15(-/-) female mice remained diabetes free compared with only 30% in the control group. Diabetes incidence was also decreased in 8.3-NOD (full name NOD Cg-Tg[TcraTcrbNY8.3]-1Pesa/DvsJ).Il15(-/-) mice expressing a highly pathogenic transgenic TCR on CD8(+) T cells. Adoptive transfer of splenocytes from diabetic NOD and 8.3-NOD donors induced disease in NOD Scid recipients but not in NOD Scid.Il15(-/-) or NOD Scid.gamma mice. Transient blockade of IL-15 signalling at the onset of insulitis prevented diabetes in NOD mice. CONCLUSIONS/ INTERPRETATION: Our results show that IL-15 is needed for the initial activation of diabetogenic CD8(+) T cells as well as for sustaining the diabetogenic potential of antigen-stimulated cells, acting on both CD8(+) T cells and on APCs. Our findings demonstrate a critical role for IL-15 in the pathogenesis of autoimmune diabetes and suggest that IL-15 is a promising therapeutic target.
AIMS/HYPOTHESIS: IL-15, induced by innate immune stimuli, promotes rheumatoid arthritis and inflammatory bowel disease. However, its role in autoimmune type 1 diabetes is unclear. Our aim is to define the role of IL-15 in the pathogenesis of diabetes in the NOD mouse model. METHODS: We generated NOD.Il15(-/-) mice expressing a polyclonal repertoire of T cell antigen receptor (TCR) or a transgenic TCR and monitored diabetes onset and insulitis. NOD Scid.Il15(-/-) (full name NOD.CB17-Prkdc (scid)/NCrCrl) and NOD Scid.gamma (full name NOD.Cg-Prkdc(scid) Il2rg ( tm1Wjl )/SzJ) mice were used to distinguish the requirement for IL-15 signalling in CD8(+) T cells and antigen-presenting cells (APCs) to induce disease. We examined the effect of blocking IL-15 signalling on diabetes onset in NOD mice. RESULTS: At 7 months of age, more than 75% of the NOD Il15(-/-) female mice remained diabetes free compared with only 30% in the control group. Diabetes incidence was also decreased in 8.3-NOD (full name NOD Cg-Tg[TcraTcrbNY8.3]-1Pesa/DvsJ).Il15(-/-) mice expressing a highly pathogenic transgenic TCR on CD8(+) T cells. Adoptive transfer of splenocytes from diabetic NOD and 8.3-NOD donors induced disease in NOD Scid recipients but not in NOD Scid.Il15(-/-) or NOD Scid.gamma mice. Transient blockade of IL-15 signalling at the onset of insulitis prevented diabetes in NOD mice. CONCLUSIONS/ INTERPRETATION: Our results show that IL-15 is needed for the initial activation of diabetogenic CD8(+) T cells as well as for sustaining the diabetogenic potential of antigen-stimulated cells, acting on both CD8(+) T cells and on APCs. Our findings demonstrate a critical role for IL-15 in the pathogenesis of autoimmune diabetes and suggest that IL-15 is a promising therapeutic target.
Authors: Jacqueline D Trudeau; Carolyn Kelly-Smith; C Bruce Verchere; John F Elliott; Jan P Dutz; Diane T Finegood; Pere Santamaria; Rusung Tan Journal: J Clin Invest Date: 2003-01 Impact factor: 14.808
Authors: K Fujihira; M Nagata; H Moriyama; H Yasuda; K Arisawa; M Nakayama; S Maeda; M Kasuga; K Okumura; H Yagita; K Yokono Journal: Diabetes Date: 2000-12 Impact factor: 9.461
Authors: Eveline Angstetra; Kate L Graham; Yuxing Zhao; Allison E Irvin; Lorraine Elkerbout; Pere Santamaria; Robyn M Slattery; Thomas W Kay; Helen E Thomas Journal: Immunol Cell Biol Date: 2011-03-08 Impact factor: 5.126
Authors: A Signore; A Annovazzi; P Giacalone; P E Beales; M G Valorani; A R Vestri; G Ruberti; S Manfrini; P Pozzilli; S Bulfone-Paus Journal: Diabetes Metab Res Rev Date: 2003 Nov-Dec Impact factor: 4.876
Authors: D Bobbala; R Kandhi; X Chen; M Mayhue; E Bouchard; J Yan; H Knecht; F Barabé; S Ramanathan; S Ilangumaran Journal: Leukemia Date: 2016-02-15 Impact factor: 11.528
Authors: Blair T Stocks; Christopher S Wilson; Andrew F Marshall; Emilee M Hoopes; Daniel J Moore Journal: J Immunol Date: 2019-05-24 Impact factor: 5.422
Authors: Connor J Dwyer; Allison L Bayer; Carmen Fotino; Liping Yu; Cecilia Cabello-Kindelan; Natasha C Ward; Kevin H Toomer; Zhibin Chen; Thomas R Malek Journal: Sci Signal Date: 2017-12-19 Impact factor: 8.192
Authors: Maximiliano Presa; Yi-Guang Chen; Alexandra E Grier; Edward H Leiter; Michael A Brehm; Dale L Greiner; Leonard D Shultz; David V Serreze Journal: J Immunol Date: 2015-08-17 Impact factor: 5.422
Authors: X-L Chen; D Bobbala; G M Rodriguez; M Mayhue; Y-G Chen; S Ilangumaran; S Ramanathan Journal: Clin Exp Immunol Date: 2013-08 Impact factor: 4.330
Authors: P T Saligrama; K A Fortner; M A Secinaro; C C Collins; J Q Russell; R C Budd Journal: Cell Death Differ Date: 2014-02-07 Impact factor: 15.828